Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 19/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1819679 | 0.92 | SLC6A9 (0.49) | SLC6A9 | |
| SCHEMBL1821283 | 0.80 | SLC6A9 (0.43) | SLC6A9 | |
| SCHEMBL1819768 | 0.80 | SLC6A9 (0.60) | SLC6A9KDM4EMEN1GAAMAPT | |
| SCHEMBL1817421 | 0.79 | SLC6A9 (0.52) | SLC6A9 | |
| SCHEMBL1819074 | 0.79 | SLC6A9 (0.74) | SLC6A9 | |
| SCHEMBL1822350 | 0.76 | SLC6A9 (0.67) | SLC6A9 | |
| SCHEMBL1818649 | 0.76 | SLC6A9 (0.58) | SLC6A9 | |
| SCHEMBL1819047 | 0.75 | SLC6A9 (0.55) | SLC6A9 | |
| SCHEMBL1819751 | 0.75 | SLC6A9 (0.58) | SLC6A9 | |
| SCHEMBL1816380 | 0.75 | SLC6A9 (0.68) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947714-B2 | Piperidine glycine transporter inhibitors | Merck, Sharp & Dohme Corp. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947714-B2 | Piperidine glycine transporter inhibitors | Merck, Sharp & Dohme Corp. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947714-B2 | Piperidine glycine transporter inhibitors | Merck, Sharp & Dohme Corp. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20090270451-A1 | Piperdine Glycine Transporter Inhibitors | MERCK & CO., INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090270451-A1 | Piperdine Glycine Transporter Inhibitors | MERCK & CO., INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090270451-A1 | Piperdine Glycine Transporter Inhibitors | MERCK & CO., INC. (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2007053400-A2 | PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270451-A1 | Piperdine Glycine Transporter Inhibitors | SLC1A2, SLC1A1, SLC1A3 | SLC6A9 19/4885KDM4E 3305/4885MEN1 4026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.